Comparative analysis of antiviral efficacy of FDA‐approved drugs against SARS‐CoV‐2 in human lung cells
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Drug repositioning represents an effective way to control the current COVID‐19 pandemic. Previously, we identified 24 FDA‐approved drugs which exhibited substantial antiviral effect against severe acute respiratory syndrome coronavirus 2 in Vero cells. Since antiviral efficacy could be altered in different cell lines, we developed an antiviral screening assay with human lung cells, which is more appropriate than Vero cell. The comparative analysis of antiviral activities revealed that nafamostat is the most potent drug in human lung cells (IC 50 = 0.0022 µM).
Article activity feed
-
-
SciScore for 10.1101/2020.05.12.090035: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources Anti-SARS-CoV-2 N protein antibody was purchased from Sino Biological Inc. (Beijing, China) Anti-SARS-CoV-2 N protein antibodysuggested: NoneAnti-SARS-CoV-2 N proteinsuggested: NoneAlexa Fluor 488 goat anti-rabbit IgG (H + L) secondary antibody and Hoechst 33342 were purchased from Molecular Probes. Alexa Fluor 488 goat anti-rabbit IgGsuggested: Noneanti-rabbit IgGsuggested: NoneExperimental Models: Cell Lines Sentences Resources Calu-3 was maintained at 37°C … SciScore for 10.1101/2020.05.12.090035: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources Anti-SARS-CoV-2 N protein antibody was purchased from Sino Biological Inc. (Beijing, China) Anti-SARS-CoV-2 N protein antibodysuggested: NoneAnti-SARS-CoV-2 N proteinsuggested: NoneAlexa Fluor 488 goat anti-rabbit IgG (H + L) secondary antibody and Hoechst 33342 were purchased from Molecular Probes. Alexa Fluor 488 goat anti-rabbit IgGsuggested: Noneanti-rabbit IgGsuggested: NoneExperimental Models: Cell Lines Sentences Resources Calu-3 was maintained at 37°C with 5% CO2 in Eagle’s Minimum Essential Medium (EMEM, ATCC), supplemented with 10% heat-inactivated fetal bovine serum (FBS) and 1X Antibiotic-Antimycotic solution (Gibco). Calu-3suggested: KCLB Cat# 30055, RRID:CVCL_0609)Viral titers were determined by plaque assays in Vero cells. Verosuggested: CLS Cat# 605372/p622_VERO, RRID:CVCL_0059)Software and Algorithms Sentences Resources DRCs were generated in Prism7 (GraphPad) software, with dose-response-inhibition nonlinear regression analysis. GraphPadsuggested: (GraphPad Prism, RRID:SCR_002798)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-